In particular, MDM2 overexpression is more likely to occur in cancers without TP53 mutations [37], as MDM2 also contains TP53-binding sites in the first intron, and is thus directly inducible by wild type TP53 [34]. This evidence concerns the gene MDM2 and cancer.